Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Eisai is a Japanese pharmaceutical company specializing in neurology and oncology therapeutics, with flagship products including Leqembi (Alzheimer's disease, co-developed with Biogen), Lenvima (oncology), and Fycompa (epilepsy). The company operates globally with significant commercial presence in Japan, US, Europe, and China, deriving approximately 40% of revenue from Japan and 30% from the Americas. Stock performance is primarily driven by Leqembi commercial uptake, Lenvima lifecycle management, and pipeline advancement in neurodegenerative diseases.
Eisai generates revenue through proprietary branded pharmaceuticals with patent protection, focusing on high-value specialty markets where clinical differentiation commands premium pricing. The company leverages co-promotion agreements (Biogen for Leqembi, Merck for Lenvima combinations) to share commercialization costs while accessing broader distribution. Pricing power derives from limited competition in epilepsy (Fycompa) and first-in-class status for Alzheimer's (Leqembi as first anti-amyloid therapy with full FDA approval). Gross margins of 78.6% reflect specialty pharma economics, though operating margins of 6.9% indicate heavy R&D investment (typically 20-25% of revenue) and commercial infrastructure costs for launch activities.
Leqembi commercial uptake metrics: quarterly prescription volumes, reimbursement coverage expansion (Medicare CMS coverage critical), infusion center capacity buildout, and patient diagnosis rates through biomarker testing
Lenvima lifecycle management: combination therapy approvals with checkpoint inhibitors (Keytruda partnership revenues), label expansions in additional tumor types, and competitive positioning against TKI alternatives
Pipeline clinical trial readouts: particularly MORAb-202 (folate receptor alpha ADC) Phase 2 data in ovarian cancer, and next-generation Alzheimer's assets beyond Leqembi
Regulatory decisions and reimbursement: FDA/EMA approvals for pipeline assets, pricing negotiations in Japan under biennial drug price revisions, and China NRDL (National Reimbursement Drug List) inclusion for key products
Alzheimer's disease treatment paradigm uncertainty: Leqembi requires confirmed amyloid pathology via PET scan or CSF testing, limiting addressable patient population. Long-term efficacy data and real-world adherence to bi-weekly infusions (versus oral competitors in development) remain unproven at scale. CMS reimbursement currently requires registry participation, creating administrative friction.
Pharmaceutical pricing pressure: Japan implements biennial drug price cuts (typically 5-10% for established products), US faces political pressure for Medicare negotiation under IRA (Inflation Reduction Act), and European markets maintain strict cost-effectiveness thresholds (NICE, HAS) that may limit Leqembi pricing power despite clinical benefits.
Patent cliff exposure: Lenvima composition of matter patents expire 2029-2030 globally, representing potential loss of $3-4B annual revenue without successful lifecycle management or pipeline replacement. Fycompa faces similar timeline with 2030 patent expiration.
Alzheimer's competitive landscape intensifying: Eli Lilly's donanemab (approved 2024) offers less frequent dosing (monthly infusions transitioning to quarterly) versus Leqembi's bi-weekly regimen, potentially capturing market share. Oral amyloid therapies in Phase 2/3 development could disrupt infusion-based model entirely by 2028-2030.
Oncology competition from next-generation targeted therapies: Lenvima faces pressure from newer VEGF/TKI inhibitors with improved safety profiles and antibody-drug conjugates in renal cell carcinoma. Checkpoint inhibitor monotherapy and combinations continue evolving, potentially displacing Lenvima combinations in treatment algorithms.
Leqembi commercialization cash burn: Estimated $1-2B annual investment in manufacturing capacity, infusion infrastructure support, and direct-to-consumer awareness campaigns through 2027. Free cash flow of $7.1B provides cushion, but sustained investment may pressure dividend sustainability (current payout ratio estimated 40-50%).
Foreign exchange volatility: Approximately 40% revenue in Japanese yen with significant dollar-denominated costs (US commercial operations, API sourcing). Yen depreciation from 110 to 150 per dollar (2021-2024) created translation headwinds. Further yen weakness could compress reported margins despite operational performance.
low - Pharmaceutical demand is largely non-discretionary and driven by disease prevalence rather than economic conditions. Oncology and neurology treatments are medically necessary with limited deferral risk. However, moderate sensitivity exists in elective diagnostic procedures (Alzheimer's biomarker testing) and patient out-of-pocket costs for high-priced therapies during economic downturns. Government healthcare budget constraints during recessions can pressure pricing and reimbursement timelines.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for long-duration growth assets like early-stage pipeline candidates, particularly impacting Leqembi's long-term revenue projections; (2) Increased financing costs for working capital and capital expenditures, though Eisai maintains low leverage (0.26 D/E) limiting direct impact. Japanese yen typically weakens when US rates rise relative to Japan's near-zero rates, creating translation tailwinds for dollar-denominated US revenue (30% of total) when repatriated.
Minimal - Pharmaceutical sales are primarily to hospitals, pharmacy benefit managers, and government payers with strong credit profiles. Accounts receivable risk is low given institutional customer base. Company maintains investment-grade credit profile with comfortable debt service coverage from operating cash flow of $30.1B.
growth-at-reasonable-price (GARP) investors focused on Leqembi's blockbuster potential in large Alzheimer's market (estimated 6.7 million US patients), balanced by established oncology cash flows and modest valuation (1.8x P/S, 13.5x EV/EBITDA below specialty pharma median of 18-20x). Also attracts dividend-oriented investors given stable payout and 2.17 current ratio supporting capital returns. Less appealing to pure growth investors given moderate 6.4% revenue growth and 6.9% operating margins reflecting investment phase.
moderate - Beta estimated 0.8-0.9 given healthcare defensive characteristics offset by binary clinical/regulatory catalysts. Stock exhibits elevated volatility around Leqembi commercial updates (quarterly earnings), pipeline readouts, and competitive developments in Alzheimer's space. Japanese ADR structure adds currency volatility and lower liquidity versus domestic Japanese listing.
